Conmed (CNMD) Research & Development (2010 - 2026)

Conmed has reported Research & Development for 17 years, with the latest figure at $16.3 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 26.15% year-over-year to $16.3 million; the trailing twelve-month figure through Mar 2026 stood at $59.3 million (up 10.21% YoY), and the FY2025 full-year result was $55.9 million, up 2.68% from the prior year.
• Research & Development for Q1 2026 stood at $16.3 million, up from $14.9 million in the prior quarter.
• The five-year high for Research & Development was $16.3 million in Q1 2026, with the low at $10.7 million in Q1 2022.
• Historically, Research & Development has averaged $13.3 million across 5 years, with a median of $13.6 million in 2024.
• Annual changes were most pronounced in 2024 — Research & Development declined 6.07% — and 2026, when it rose 26.15%.
• Conmed's Research & Development stood at $12.2 million in 2022, then grew by 14.8% to $14.0 million in 2023, then decreased by 6.07% to $13.2 million in 2024, then rose by 13.08% to $14.9 million in 2025, then increased by 9.62% to $16.3 million in 2026.
• The last three Research & Development figures came in at $16.3 million (Q1 2026), $14.9 million (Q4 2025), and $13.9 million (Q3 2025), per Business Quant data.